Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis.
Llanos-Cuentas A, Calderón W, Cruz M, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Bertholet S, Laughlin EM, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM. Llanos-Cuentas A, et al. Among authors: piazza fm. Vaccine. 2010 Oct 28;28(46):7427-35. doi: 10.1016/j.vaccine.2010.08.092. Epub 2010 Sep 17. Vaccine. 2010. PMID: 20851080 Clinical Trial.
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.
Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Kahn SJ, Beckmann AM, Pine SO, Cowgill KD, Reed SG, Piazza FM. Nascimento E, et al. Among authors: piazza fm. Vaccine. 2010 Sep 14;28(40):6581-7. doi: 10.1016/j.vaccine.2010.07.063. Epub 2010 Aug 3. Vaccine. 2010. PMID: 20688040 Clinical Trial.
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis.
Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. Chakravarty J, et al. Among authors: piazza fm. Vaccine. 2011 Apr 27;29(19):3531-7. doi: 10.1016/j.vaccine.2011.02.096. Epub 2011 Mar 15. Vaccine. 2011. PMID: 21414377 Clinical Trial.
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG; TBVPX-113 Study Team. Coler RN, et al. Among authors: piazza fm. NPJ Vaccines. 2018 Sep 4;3:34. doi: 10.1038/s41541-018-0057-5. eCollection 2018. NPJ Vaccines. 2018. PMID: 30210819 Free PMC article.
Vaccines for the leishmaniases: proposals for a research agenda.
Working Group on Research Priorities for Development of Leishmaniasis Vaccines; Costa CH, Peters NC, Maruyama SR, de Brito EC Jr, Santos IK. Working Group on Research Priorities for Development of Leishmaniasis Vaccines, et al. PLoS Negl Trop Dis. 2011 Mar 29;5(3):e943. doi: 10.1371/journal.pntd.0000943. PLoS Negl Trop Dis. 2011. PMID: 21468307 Free PMC article. No abstract available.
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.
de Bruyn G, Gordon DL, Steiner T, Tambyah P, Cosgrove C, Martens M, Bassily E, Chan ES, Patel D, Chen J, Torre-Cisneros J, Fernando De Magalhães Francesconi C, Gesser R, Jeanfreau R, Launay O, Laot T, Morfin-Otero R, Oviedo-Orta E, Park YS, Piazza FM, Rehm C, Rivas E, Self S, Gurunathan S. de Bruyn G, et al. Among authors: piazza fm. Lancet Infect Dis. 2021 Feb;21(2):252-262. doi: 10.1016/S1473-3099(20)30331-5. Epub 2020 Sep 15. Lancet Infect Dis. 2021. PMID: 32946836 Clinical Trial.
Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.
Piazza FM, Virta M, Paassilta M, Ukkonen B, Ahonen A, Esteves-Jaramillo A, Forsten A, Seppa I, Ding J, Neveu D, Jordanov E, Dhingra MS. Piazza FM, et al. Hum Vaccin Immunother. 2022 Dec 31;18(1):1-10. doi: 10.1080/21645515.2021.1902701. Epub 2021 Jun 4. Hum Vaccin Immunother. 2022. PMID: 34085900 Free PMC article.
26 results